A share price of Adaptive Biotechnologies Corp [ADPT] is currently trading at $9.31, up 1.75%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ADPT shares have gain 2.42% over the last week, with a monthly amount glided 22.34%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Adaptive Biotechnologies Corp [NASDAQ: ADPT] stock has seen the most recent analyst activity on March 21, 2025, when Goldman upgraded its rating to a Buy but kept the price target unchanged to $9 for it. On January 05, 2023, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $15 on the stock. Piper Sandler upgraded its rating to a Overweight and increased its price target to $14 on December 21, 2022. Credit Suisse initiated its recommendation with a Underperform and recommended $8 as its price target on August 25, 2022. Piper Sandler started tracking with a Neutral rating for this stock on June 03, 2022, and assigned it a price target of $7.50. In a note dated February 16, 2022, JP Morgan reiterated an Overweight rating on this stock and revised its target price from $75 to $50.
Adaptive Biotechnologies Corp experienced fluctuations in its stock price throughout the past year between $2.99 and $10.28. Currently, Wall Street analysts expect the stock to reach $12.33 within the next 12 months. Adaptive Biotechnologies Corp [NASDAQ: ADPT] shares were valued at $9.31 at the most recent close of the market. An investor can expect a potential return of 32.44% based on the average ADPT price forecast.
Analyzing the ADPT fundamentals
Trailing Twelve Months sales for Adaptive Biotechnologies Corp [NASDAQ:ADPT] were 189.53M which represents 25.24% growth. Gross Profit Margin for this corporation currently stands at 0.61% with Operating Profit Margin at -0.71%, Pretax Profit Margin comes in at -0.75%, and Net Profit Margin reading is -0.75%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.66 and Total Capital is -0.32. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.46.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.01 points at the first support level, and at 8.71 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.65, and for the 2nd resistance point, it is at 9.99.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Adaptive Biotechnologies Corp [NASDAQ:ADPT] is 2.92. Further, the Quick Ratio stands at 2.82, while the Cash Ratio is 0.58. Considering the valuation of this stock, the price to sales ratio is 7.46, the price to book ratio is 7.43.
Transactions by insiders
Recent insider trading involved PISKEL KYLE, Chief Financial Officer, that happened on May 16 ’25 when 1929.0 shares were sold. Chief Scientific Officer, ROBINS HARLAN S completed a deal on May 01 ’25 to sell 68412.0 shares. Meanwhile, Officer Harlan Robins bought 68412.0 shares on May 01 ’25.
